Abstract
A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic groups and identify a very-low risk as well as a very-high risk group with a 3-year WM-related death rate of 0, 10, 14, 38, and 48% (p < 0.001) and 10-year survival rate of 84, 59, 37, 19, and 9% (p < 0.001). We evaluated this staging system separately in patients >65 years and <65 years, according to the reason for initiation of treatment, among patients receiving frontline rituximab or in patients treated primarily without rituximab. With further validation before clinical use, this revised IPSSWM could improve WM patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:110–5.
Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, et al. Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica. 2015;100:e446–9.
Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood. 2009;113:793–6.
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s Macroglobulinemia. Blood. 2016;128:1321–8.
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70.
Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.
Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P. et al. Greek Myeloma Study Group Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom’s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk. Res. 2010;34:1340–3.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372:1430–40.
Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241–50.
Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:116–20.
Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med. Res. Methodol. 2013;13:33.
Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016;9:229–55.
Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2016;34:184–92.
Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin. Br J Haematol. 2015;168:239–45.
Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014;93:1305–12.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.
Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006;133:158–64.
Buske C, Sadullah S, Kastritis E, Tedeschi A, Garcia-Sanz R, Bolkun L, et al. Treatment and outcome patterns in European patients with Waldenstrom’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5:e299–309.
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, et al. Diagnosis and management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017;3:1257–65.
Dimopoulos MA, Kastritis E, Delimpassi S, Zomas A, Kyrtsonis MC, Zervas K. The international prognostic scoring system for Waldenstrom’s macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica. 2008;93:1420–2.
Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, et al. Phase 3 rial of Ibrutinib plus Rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med. 2018;378:2399–410.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–33.
Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791–6.
Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, et al. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018;93:187–94.
Treon SP, Xu L, Hunter Z. MYD88 mutations and response to Ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;373:584–6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
EKastritis has received honoraria from Amgen, Genesis Pharma, Janssen, Takeda, Prothena; PM has consulting or advisory role to Janssen; AD has consulting or advisory role to MSD; LY has received honoraria from Abbvie, Janssen, Roche, Gilead and has consulting or advisory role to Abbvie, Roche, Janssen, Gilead, has research funding from Roche & Janssen; KL has received honoraria from Novartis, has consulting or advisory role with Takeda, Amgen, Gilead, Novartis and has received research funding from Roche, Novartis, Takeda, Sandoz, Teva, Mundipharma; EH has received honoraria from Janssen, Roche, Winmedica; MV has advisory role to Janssen and Roche; NG has received honoraria from Takeda, Amgen, Janssen, Genesis Pharma and has a consulting or advisory role to Takeda, Amgen, Janssem, Genesis Pharma; GM has participated in advisory boards of Janssen, Takeda, Ionis, MAD has received honoraria from Amgen, Celgene, Janssen, Takeda. The remaining authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Kastritis, E., Morel, P., Duhamel, A. et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia 33, 2654–2661 (2019). https://doi.org/10.1038/s41375-019-0431-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0431-y
This article is cited by
-
Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia
Annals of Hematology (2024)
-
Early progression is associated with worse survival in patients with Waldenström’s macroglobulinemia
Holistic Integrative Oncology (2024)
-
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia
Current Hematologic Malignancy Reports (2024)
-
Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects
Annals of Hematology (2023)
-
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Clinical Hematology International (2022)